Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Get Free Report) gapped down prior to trading on Monday. The stock had previously closed at $3.92, but opened at $3.38. Aclaris Therapeutics shares last traded at $3.4640, with a volume of 2,287,360 shares trading hands.
Wall Street Analysts Forecast Growth
A number of analysts have commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Monday, September 21st. Craig Hallum set a $9.00 price objective on shares of Aclaris Therapeutics in a research note on Wednesday, October 28th. Wall Street Zen upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, October 24th. HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Aclaris Therapeutics in a report on Wednesday, October 28th. Finally, Canaccord Genuity Group decreased their target price on shares of Aclaris Therapeutics from $13.00 to $12.00 and set a “buy” rating for the company in a research report on Tuesday. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Aclaris Therapeutics presently has an average rating of “Buy” and a consensus price target of $10.67.
Read Our Latest Report on ACRS
Aclaris Therapeutics Stock Down 6.4%
The firm has a 50 day moving average price of $4.33 and a 200 day moving average price of $4.53.
Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last announced its earnings results on Thursday, November 5th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.16) by $0.04. Aclaris Therapeutics had a negative return on equity of 59.19% and a negative net margin of 1,244.09%. The company had revenue of $1.48 million for the quarter, compared to analysts’ expectations of $1.27 million. As a group, equities research analysts predict that Aclaris Therapeutics, Inc. will post -0.56 EPS for the current year.
Hedge Funds Weigh In On Aclaris Therapeutics
A number of hedge funds have recently bought and sold shares of ACRS. Aquatic Capital Management LLC purchased a new position in shares of Aclaris Therapeutics in the 3rd quarter worth approximately $284,000. Goldman Sachs Group Inc. grew its holdings in shares of Aclaris Therapeutics by 96.0% in the third quarter. Goldman Sachs Group Inc. now owns 1,193,916 shares of the biotechnology company’s stock valued at $6,280,000 after acquiring an additional 584,758 shares in the last quarter. Lighthouse Investment Partners LLC bought a new position in shares of Aclaris Therapeutics in the third quarter valued at approximately $474,000. Integral Health Asset Management LLC bought a new position in shares of Aclaris Therapeutics in the third quarter valued at approximately $1,052,000. Finally, Marshall Wace LLP bought a new position in shares of Aclaris Therapeutics in the third quarter valued at approximately $3,318,000. 98.34% of the stock is owned by hedge funds and other institutional investors.
About Aclaris Therapeutics
Aclaris Therapeutics is a biopharmaceutical company focused on discovering and developing treatments for immuno-inflammatory diseases. Its research programs include small-molecule therapies designed to target pathways involved in inflammation and immune responses. The company’s development portfolio has included candidates for dermatologic and other inflammatory conditions. Aclaris previously developed ESKATA, a topical treatment for raised seborrheic keratoses that received U.S. regulatory approval in 2017.
Further Reading
- Five stocks we like better than Aclaris Therapeutics
- 3 Stocks Flashing Buy Signals With Historical Win Rates Above 85% After the Sell-Off
- Disney Has the Magic Touch: Dividend Growth and Buybacks Could Fuel a Breakout
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
